Crinecerfont Capsule — FDA Drug Shortage

To Be Discontinued — Neurocrine Biosciences, Inc.

The FDA lists a drug shortage record for Crinecerfont Capsule (capsule) from Neurocrine Biosciences, Inc. with status To Be Discontinued. The shortage was first posted on Apr 28, 2026.

Shortage details

Status
To Be Discontinued
Company
Neurocrine Biosciences, Inc.
Package NDC
70370-5025-1
Dosage Form
Capsule
Presentation
Crenessity, Capsule, 25 mg (NDC 70370-5025-1)
Initial Posting
Apr 28, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.